Anti-drug antibodies (ADAs) can hinder development of complex therapeutic modalities, like bispecific molecules and gene therapies. It is critical to understand the potential for ADA formation by the host of these therapeutic drug products as well as the impact of ADA on critical in vivo parameters such as PK and drug clearance rate. Having a robust immunogenicity assay for accurate evaluation of ADA in animal models is important for enabling effective decision-making during development. Learn how Prolytix developed a robust anti-drug antibody assay capable of detection at the requisite sensitivity and enabled meaningful interpretation of PK data obtained from the preclinical animal model.